This study aims to evaluate the safety of Beovu kit for intravitreal injection in clinical use in diabetic macular edema (DME) patients.~The observation period is 1 year (52 weeks) from the first Beovu administration in the primary treated eye.~In patients discontinuing treatment with Beovu in the primary treated eye before Week 52, the following observation periods will apply.~Date of last Beovu dose + 90 days* in primary treated eye > Week 52: up to Week 52~Date of last Beovu dose + 90 days* in primary treated eye ≤ Week 52: up to last dosing date in the primary treated eye + 90 days *90 days: to collect as much data as possible considering clinical effects
This is a primary data collection-based observational special drug-use surveillance to be conducted in accordance with the Good Post-marketing Study Practice (GPSP) ordinance.